Attenuated hepatitis a virus vaccine which grows in MRC-5 cells

US6180110A · kind A · utility

Assignee

• The United States of America, as represented by the Department of Health and Human Services · US

Inventors

• Ann W. Funkhouser · Ellicott City, US
• Suzanne U. Emerson · Rockville, US
• Robert H. Purcell · Boyds, US
• Eric D'Hondt · Ottenburg, BE

Key dates

• Filing date: Apr 17, 1995
• Grant date: Jan 30, 2001
• Expiry date: Apr 17, 2015

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A live hepatitis A virus (HAV) adapted to grow in MRC-5 cells is described, the HAV preferably characterized by suitable attenuation for effective vaccine administration to humans and animals without inactivation. Methods for adapting HAV to grow in MRC-5 cells, vaccine compositions comprising the attenuated HAV, and methods of vaccinating humans against HAV infection are also described.